Literature DB >> 20436290

The molecular dynamics of MDM2.

Judith Nicholson, Ted R Hupp.   

Abstract

The pro-oncogenic signals of a vast number of anti-cancer drug targets are mediated by protein-protein interactions. This has made such targets less attractive to classic drug discovery programmes. New paradigms in the protein science field have revealed, however, that many protein-protein complexes are stabilized by an interaction between an intrinsically disordered peptide motif and a highly structured globular domain. This type of protein-protein interaction embodied by the MDM2-p53 complex can form a drugable interface. Extensive research has already uncovered the structure of the MDM2-bound p53 peptide to create p53 mimetics like Nutlin, but there has been less emphasis on understanding the dynamic nature of MDM2 itself. The work summarized by Joseph et al. forms a comprehensive and innovative roadmap using molecular dynamics simulations that provide solutions for understanding the flexible nature of a peptide-protein interface. This includes concepts on the plasticity of the peptide-binding groove and induced-fit mechanisms that explain the diversity of linear peptide motifs accommodated by globular domains. The success of molecular dynamics should inspire us to build further the structural biology of full-length MDM2 and other challenging oncoproteins for developing rules on how to develop small molecules that allosterically regulate multi-protein complexes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20436290     DOI: 10.4161/cc.9.10.11597

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  6 in total

1.  Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.

Authors:  Sudipta Samanta; Sanchita Mukherjee
Journal:  J Comput Aided Mol Des       Date:  2017-09-04       Impact factor: 3.686

2.  A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function.

Authors:  Jennifer A Fraser; Borivoj Vojtesek; Ted R Hupp
Journal:  J Biol Chem       Date:  2010-09-17       Impact factor: 5.157

3.  Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.

Authors:  Xiaosong Wu; Jumei Shi; Yi Wu; Yi Tao; Jun Hou; Xiuqin Meng; Xiaojing Hu; Ying Han; Wei Jiang; Siyuan Tang; Maurizio Zangari; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

4.  p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study.

Authors:  Peng Zhang; Song-Ke Wu; Ying Wang; Zi-Xuan Fan; Chu-Rong Li; Mei Feng; Peng Xu; Wei-Dong Wang; Jin-Yi Lang
Journal:  Oncol Lett       Date:  2014-10-24       Impact factor: 2.967

5.  Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit.

Authors:  Bo Cao; Ziling Fang; Peng Liao; Xiang Zhou; Jianping Xiong; Shelya Zeng; Hua Lu
Journal:  Oncotarget       Date:  2017-10-06

Review 6.  Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Authors:  Lucia Haronikova; Ondrej Bonczek; Pavlina Zatloukalova; Filip Kokas-Zavadil; Martina Kucerikova; Philip J Coates; Robin Fahraeus; Borivoj Vojtesek
Journal:  Cell Mol Biol Lett       Date:  2021-12-15       Impact factor: 5.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.